21 July 2022 
EMA/630579/2022  
Human Medicines Division 
Statement indicating compliance with the agreed completed 
paediatric investigation plan  
Medicinal product  
Imbruvica/ ibrutinib 
Pharmaceutical form(s): 
See Annex A of the CHMP Opinion 
Strength(s): 
See Annex A 
Route(s) of administration: 
See Annex A 
Packaging and package 
See Annex A 
size(s): 
Number(s)in the Community 
See Annex A 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH: 
Janssen-Cilag International N.V. 
Turnhoutseweg 30 
Beerse 
2340 Antwerp 
BELGIUM 
Procedure  
Procedure number: 
EMEA/H/C/003791/II/0074 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and 
in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
the development of this product has complied with all measures in the agreed paediatric 
investigation plan P/0337/2021. All studies in the agreed paediatric investigation plan P/0337/2021 
were conducted after the entry into force of that Regulation, 
-the Summary of Product Characteristics reflects the results of studies conducted in compliance with 
this agreed paediatric investigation plan. 
In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating 
compliance with the agreed completed paediatric investigation plan P/0337/2021 is included in the 
technical dossier. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
 An agency of the European Union      
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
